Paradigm Biopharmaceuticals has hay fever study published
Shares in Paradigm are trading up over 50% year to date, priced at $0.59.
Company
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a drug repurposing company driven by core competencies and experience at board and executive level in clinical and commercial pharmaceutical development. The company’s approach is to take an existing approved drug, which has demonstrated safety in its approved indications, and repurposing the drug in a new patented therapeutic application. Paradigm’s pipeline indications cover the use of pharmaceutical compound Pentosan Polysulfate Sodium (PPS), supported by full patent and IP protection and its immediate commercial focus is the repurposing of PPS for the treatment of Osteoarthritis (OA).
175 stories · page 9 of 9
Paradigm Biopharmaceuticals receives valuable grant
First dosing in the Phase 2a clinical trial is expected during this quarter.
Paradigm Biopharmaceuticals brings Phase 2 milestone news flow to Spotlight CEO Sessions
Find out more from Paul Rennie at Proactive's CEO Sessions.
The Hydroponics Company brings immediate cash flow to Spotlight CEO Sessions
Find out more from Andrew Beehag at Proactive's CEO Sessions.
Stonewall Resources to showcase near-term gold production at Spotlight CEO Sessions
Find out more from Robert Thomson at Proactive's CEO Sessions.
White Rock Minerals to show case silver-zinc at Spotlight CEO Sessions
Find out more from Matthew Gill at Proactive's CEO Sessions.
Paradigm Biopharmaceuticals treats final patient in hay fever trial
The last patient in a Phase 2 hay fever trial has been treated.
Paradigm Biopharmaceuticals gets cash boost from rebate
Paradigm plans to conduct a clinical trial for Ross River in June 2017.
Paradigm Biopharmaceuticals to test Ross River treatment
Paradigm plans to conduct a clinical trial for Ross River in June 2017.
Paradigm Biopharmaceuticals shines under broker spotlight
Paradigm has been attracting the attention of brokers.
Paradigm Biopharmaceuticals completes recruitment for hay fever trial
Paradigm Biopharmaceuticals (ASX:PAR) has completed the recruitment of all forty subjects in its clinical trial of Rhinosul for hay fever.
Paradigm Biopharmaceuticals Ltd to begin allergic rhinitis trial in Sweden
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has received approval from the Swedish Medical Products Authority (MPA) to commence phase 2a allergic rhinitis trial of Rhinosul in Sweden.
Paradigm Biopharmaceuticals heads to market
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has been granted a trading halt by the ASX this morning, pending details of a capital raising.